熱門資訊> 正文
BLA重新提交接受黑色素瘤资产后，Replimune股价飙升108%
2025-10-20 21:00
- The US FDA has accepted Replimune's (NASDAQ:REPL) BLA submission of RP1 in combination with Bristol Myers Squibb's (BMY) Opdivo (nivolumab) for advanced melanoma.
- Shares are up ~108% in pre-market trading Monday.
- RP1 would be used in patients who have failed on a treatment regimen containing a PD-1 inhibitor.
- The candidate has an FDA action date of April 10, 2026.
- In July, the FDA issued a Complete Response Letter for Replimune, citing inadequacy with the company's IGNYTE trial. Shares tumbled in response.
More on Replimune Group
- Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating
- Replimune Group: The Prospects For FDA Approval After Rejection
- Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
- Replimune cut to Underweight at J.P. Morgan on further headline risk
- Replimune down amid uncertainty over accelerated approval
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
